> ## Content Index
> Fetch the complete content index at: https://www.pennystocks.news/llms.txt
> Use this file to discover other available public pages before exploring further.

# A Tiny Biotech Says Its Ebola Drug Beat Remdesivir in the Lab
- URL: https://www.pennystocks.news/dcoy-a-tiny-biotech-says-its-ebola-drug-beat-remdesivir-in-t/
- Published: 2026-09-23T23:00:02.000Z
- Updated: 2026-09-23T23:00:02.000Z
- Description: The result comes from cell-based tests and a single AI design cycle. The company says it will fund what comes next through government grants rather than new shares — and that an approved drug could carry a voucher worth up to $180 million.
- Author: PennyStocksNews Team
- Tags: nasdaq, ticker-dcoy

The drug was designed by an algorithm. In cell tests against live Ebola virus, it **outperformed remdesivir by a factor of seven**, the company says. That is the claim; the work ahead is proving it holds in animals.

Decoy Therapeutics Inc. NASDAQ: DCOY 

Shares in Decoy Therapeutics **closed 21.09% higher at $3.10** after the company published the results, on dollar volume of about $559 million.

For holders, the core question is whether the lab data survives animal testing — and whether government funding will pay for that next stage.

Decoy's AI platform produced the candidate against filoviruses — the viral family that includes Ebola and Marburg — in what the company calls a single optimization cycle. In cell-based assays, the compound hit a potency reading of **1.56 μM against wild-type Ebola Zaire**. That measures the concentration needed to block half the virus's activity in a dish; lower means the drug works at a smaller dose. The same compound hit **1.04 μM against Marburg virus**.

The company plans to seek approval through the FDA's Animal Rule, a pathway that lets drugs targeting lethal pathogens win regulatory clearance through animal studies rather than human efficacy trials. Decoy says it is pursuing **non-dilutive government grants** and biodefense partnerships to fund the work — meaning it does not plan to issue new shares to pay for it.

There is a second potential payoff. A successful filovirus approval would make Decoy eligible for a Priority Review Voucher — a certificate that speeds the FDA's review of any later drug application and can be sold to another pharmaceutical company. The company says recent voucher transactions have ranged **between $100 million and $180 million**.

The program remains at the preclinical stage. No animal data has been published, no government grant has been announced, and the company has not given a timeline. The distance from a cell assay to an approved drug is long, and what sits at the start of that road is an AI-designed molecule that worked in a dish.